TY - T1的慢性阻塞性肺病痰嗜酸性粒细胞;关系的影响血液嗜酸性粒细胞和吸入PDE4抑制摩根富林明-欧洲呼吸杂志》乔和J - 10.1183/13993003.00237 -2020欧元SP - 2000237 AU -戴夫·辛格盟Henrik Watz盟- Kai迈克尔Beeh AU -奥利弗Kornmann盟-布莱恩泄密者非盟-布兰登·科尔根盟杰Lucci盟Aida Emirova AU -玛丽安娜Nandeuil盟黛博拉澳网AU -黛博拉Balzano盟Mirco Govoni Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/03/17/13993003.00237 - 2020. -抽象N2 -慢性阻塞性肺疾病(COPD)患者有更高的在航空和外周血嗜酸性粒细胞数量展示一个更大的临床反应吸入激素(ICS) [1 - 3]。此外,口服phosphodiesterase-4的效果(PDE4抑制剂roflumilast)在严重的慢性阻塞性肺病急性加重慢性支气管炎患者,ICS和长期治疗的支气管扩张剂,也似乎更大更高的血嗜酸性粒细胞计数[4]。负责这些微分药物效应的机制仍有待定义,但可能与增加2型炎症和/或减少的殖民气道细菌在慢性阻塞性肺病患者嗜酸性粒细胞(5、6),导致不同的反应抗炎药物。血液与痰嗜酸性粒细胞中观察到一些,但不是所有的研究[7]。准确的痰液嗜酸性粒细胞计数测量要求质量好的样品做出cytospins嗜酸性粒细胞可以明确计算;变量的痰样本质量,尤其是在多中心研究,会影响显示的能力与血液嗜酸性粒细胞计数之间的关系。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。这里发表周全之前接受的形式排版,我们的生产团队。这些生产过程完成后,作者已经批准结果证明,本文将最新一期的ERJ在线。请打开或下载PDF查看这篇文章。Conflict of interest: Dr. Singh reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from Cipla, personal fees from Genentech, personal fees from GlaxoSmithKline, personal fees from Glenmark, personal fees from Menarini, personal fees from Mundipharma, personal fees from Novartis, personal fees from Peptinnovate, personal fees from Pfizer, personal fees from Pulmatrix, personal fees from Theravance, personal fees from Verona, outside the submitted work.Conflict of interest: Dr. Watz reports personal fees from Chiesi, during the conduct of the study; personal fees from Bayer, personal fees from GSK, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from AstraZeneca, personal fees from BerlinChemie, personal fees from Roche, outside the submitted work.Conflict of interest: KMB declares that no personal payments were received from any pharmaceutical entity in the past 5 years. KMB is a full time employee of insaf Respiratory Research Institute. The institution has received compensation for services on advisory boards or consulting for Ablynx, Almirall, AstraZeneca, Berlin Chemie, Boehringer, Chiesi, Cytos, Mundipharma, Novartis, Pohl Boskamp, Zentiva. The institution has received compensation for speaker activities in scientific meetings supported by Almirall, AstraZeneca, Berlin Chemie, Boehringer, Cytos, ERT, GSK, Novartis, Pfizer, Pohl Boskamp, Takeda. The institution has further received compensation for design and performance of clinical trials from Almirall, Altana/Nycomed, AstraZeneca, Boehringer, Cytos, GSK, Infinity, Medapharma, MSD, Mundipharma, Novartis, Parexel, Pearl Therapeutics, Pfizer, Revotar, Teva, Sterna, and Zentiva.Conflict of interest: Dr. Kornmann reports other from Chiesi, during the conduct of the study; personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from GlaxoSmithKline, personal fees from Sanofi, from Novartis, outside the submitted work.Conflict of interest: Dr. Leaker has nothing to disclose.Conflict of interest: Dr. Colgan has nothing to disclose.Conflict of interest: Dr. Lucci reports and I am an employee of Chiesi, the sponsor of the trial.Conflict of interest: Dr. Emirova reports and I am an employee of Chiesi, the sponsor of the trial.Conflict of interest: Dr. Nandeuil reports and I am an employee of Chiesi, the sponsor of the trial.Conflict of interest: Dr. Santoro reports and I am an employee of Chiesi, the sponsor of the trial.Conflict of interest: Dr. Balzano reports and I am an employee of Chiesi, the sponsor of the trial.Conflict of interest: Dr. Govoni reports and I am an employee of Chiesi, the sponsor of the trial. ER -